Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: A randomised, single-blind, placebo-controlled, phase 2 trial

The Lancet Infectious Diseases

Volumn 12, Issue 8, 2012, Pages 597-607

  Richmond, Peter C ^a   Marshall, Helen S ^b   Nissen, Michael D ^c   Jiang, Qin ^d   Jansen, Kathrin U ^e   Garcés Sánchez, Maria ^f   Martinón Torres, Federico ^g   Beeslaar, Johannes ^h   Szenborn, Leszek ⁱ   Wysocki, Jacek ^j   Eiden, Joseph ^e   Harris, Shannon L ^e   Jones, Thomas R ^e   Perez, John L ^e  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d Pfizer Vaccine Research Statistics   (United States)

^e Pfizervaccine Research   (United States)

^f CS Nazaret   (Spain)

^g Santiago University Clinical Hospital   (Spain)

^h PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

ⁱ WROCLAW MEDICAL UNIVERSITY   (Poland)

^j POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCAL SEROGROUP B BIVALENT RECOMBINANT LIPOPROTEIN 2086 VACCINE; MENINGOCOCCUS VACCINE; PLACEBO; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTHRALGIA; ARTICLE; AUSTRALIA; BACTERIAL STRAIN; CHILL; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN COMPLEMENT SERUM BACTERICIDAL ASSAY; IMMUNIZATION; IMMUNOASSAY; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; MALE; MENINGOCOCCOSIS; MYALGIA; NAUSEA; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; POLAND; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SINGLE BLIND PROCEDURE; SPAIN; VOMITING;

ADOLESCENT; ADULT; CHILD; COMPLEMENT FACTOR H; FATIGUE; FEMALE; FEVER; HEADACHE; HUMANS; INJECTIONS; LIPOPROTEINS; MALE; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; PAIN; RECOMBINANT PROTEINS; SERUM BACTERICIDAL ANTIBODY ASSAY; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84864147338     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70087-7     Document Type: Article

References (34)

1. Granoff DM, Harrison LH, Borrow R Meningococcal vaccines. Vaccines 2008, 399-434. Saunders Elsevier, Philadelphia. 5th edn. S.A. Plotkin, W.A. Orenstein (Eds.).
2. Christensen H, May M, Bowen L, Hickman M, Trotter CL Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10:853-861.
3. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet 2006, 367:397-403.
4. Bilukha OO, Rosenstein N Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005, 54:1-21.
5. Girard MP, Preziosi MP, Aguado MT, Kieny MP A review of vaccine research and development: meningococcal disease. Vaccine 2006, 24:4692-4700.
6. Madico G, Welsch JA, Lewis LA, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006, 177:501-510.
7. Goldschneider I, Gotschlich EC, Artenstein MS Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969, 129:1307-1326.
8. Borrow R, Carlone GM, Rosenstein N, et al. Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 2006, 24:5093-5107.
9. Pace D, Pollard AJ, Messonier NE Quadrivalent meningococcal conjugate vaccines. Vaccine 2009, 27(suppl 2):B30-B41.
10. Bruge J, Bouveret-Le Cam N, Danve B, Rougon G, Schulz D Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 2004, 22:1087-1096.
11. Jelfs J, Munro R, Wedege E, Caugant DA Sequence variation in the porA gene of a clone of Neisseria meningitidis during epidemic spread. Clin Diagn Lab Immunol 2000, 7:390-395.
12. Tondella ML, Popovic T, Rosenstein NE, et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. J Clin Microbiol 2000, 38:3323-3328.
13. Martin DR, Ruijne N, McCallum L, O'Hallahan J, Oster P The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol 2006, 13:486-491.
14. Lo H, Tang CM, Exley RM Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development. Lancet Infect Dis 2009, 9:418-427.
15. Masignani V, Comanducci M, Giuliani MM, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003, 197:789-799.
16. Fletcher LD, Bernfield L, Barniak V, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004, 72:2088-2100.
17. Lucidarme J, Tan L, Exley RM, Findlow J, Borrow R, Tang CM Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein. Clin Vaccine Immunol 2011, 18:1002-1014.
18. McNeil LK, Murphy E, Zhao XJ, et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine 2009, 27:3417-3421.
19. Jiang HQ, Hoiseth SK, Harris SL, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010, 28:6086-6093.
20. Murphy E, Andrew L, Lee KL, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009, 200:379-389.
21. Pajon R, Beernink PT, Harrison LH, Granoff DM Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 2010, 28:2122-2129.
22. Marshall H, Nissen MD, Richmond P, et al. A randomized, placebo-controlled, double-blind, phase 1 trial of ascending doses of meningococcal group B rLP2086 vaccine in healthy adults. 16th International Pathogenic Conference; Rotterdam, the Netherlands; Sept 7-12, 2008. P213.
23. Richmond P, Marshall H, Nissen M, et al. A randomized, observer-blinded, active control, phase 1 trial of meningococcal serogroup B rLP2086 vaccine in healthy children and adolescents aged 8 to 14 years. 16th International Pathogenic Conference; Rotterdam, the Netherlands; Sept 7-12, 2008. P212.
24. Richmond P, Marshall H, Sheldon E, et al. Safety and immunogenicity of serogroup B Neissseria meningitidis (MnB) rLP2086 vaccine in adults and adolescent subjects: overview of 3 clinical trials. 17th International Pathogenic Conference; Banff, AB, Canada; Sept 11-16, 2010. VW04.
25. Marshall H, Nissen M, Richmond P, et al. Safety and immunogenicity of bivalent rLP2086 vaccine for serogroup B meningococcal disease. Communicable Disease Control Conference 2011; Canberra, Australia; April 4-6, 2011.
26. Marshall H, Nissen M, Richmond P, et al. Safety and immunogenicity and blood collection study for assay development in adults receiving bivalent rLP2086 vaccine. 11th European Monitoring Group for Meningococci (EMGM) Meeting; Ljubljana, Slovenia; May 18-20, 2011. P046.
27. Marshall H, Richmond P, Nissen MD, et al. Phase 1 randomized controlled clinical trial of safety and immunogenicity of a meningococcal B bivalent vaccine in healthy toddlers. 29th Annual Meeting of the European Society for Paediatric Infectious Diseases; The Hague, The Netherlands; June 7-11, 2011. 1246.
28. Guidance for industry: validation of analytical procedures International Conference on Harmonisation, (accessed April 26, 2012). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073381.pdf.
29. Dunphy KY, Beernink PT, Brogioni B, et al. Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood. Infect Immun 2011, 79:353-359.
30. Davila S, Wright VJ, Khor CC, et al. Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat Genet 2010, 42:772-776.
31. Santolaya ME, O'Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012, 379:617-624.
32. Keiser PB, Biggs-Cicatelli S, Moran EE, et al. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 2011, 29:1413-1420.
33. Bonvehi P, Boutriau D, Casellas J, Weynants V, Feron C, Poolman J Three doses of an experimental detoxified L3-derived lipooligosaccharide meningococcal vaccine offer good safety but low immunogenicity in healthy young adults. Clin Vaccine Immunol 2010, 17:1460-1466.
34. Feiring B, Fuglesang J, Oster P, et al. Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine. Clin Vaccine Immunol 2006, 13:790-796.